Sai Life Sciences' Q4 FY 2025-26 Quarterly Results

Result Summary

• Sai Life Sciences Ltd reported a 9.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 4.8%.
• Its expenses for the quarter were up by 13.3% QoQ and 1.8% YoY.
• The net profit increased 3.8% QoQ and increased 18.1% YoY.
• The earnings per share (EPS) of Sai Life Sciences Ltd stood at 4.87 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Sai Life Sciences Ltd is a prominent player in the pharmaceutical industry, focusing on the development, manufacture, and supply of complex pharmaceutical compounds. The company is known for its comprehensive contract research and manufacturing services (CRAMS) provided to global pharmaceutical innovators. Sai Life Sciences has established a strong presence in both the domestic and international markets, earning its reputation through quality products and services. While specific recent developments are not detailed in the provided data, the company has been consistently recognized for its contributions to the industry and commitment to innovation.

Revenue

In the fourth quarter of the fiscal year 2026, Sai Life Sciences Ltd reported a total income of ₹617.66 crores. This marks an increase from the previous quarter's income of ₹564.84 crores, reflecting a quarter-over-quarter (QoQ) growth of 9.4%. Additionally, compared to the same quarter in the previous fiscal year, where total income was ₹589.11 crores, the company achieved a year-over-year (YoY) growth of 4.8%. The upward trend in revenue indicates the company’s capacity to expand its operations and potentially broaden its market reach during this period.

Profitability

Sai Life Sciences Ltd recorded a profit before tax of ₹139.23 crores in Q4FY26, showing an increase from the previous quarter's figure of ₹134.17 crores, which corresponds to a 3.8% rise on a QoQ basis. When compared to Q4FY25, where the profit before tax was ₹118.80 crores, there is a notable YoY increase of 17.2%. The profit after tax for Q4FY26 was reported at ₹104.24 crores, compared to ₹100.38 crores in Q3FY26 and ₹88.27 crores in Q4FY25, indicating a QoQ improvement of 3.8% and a YoY growth of 18.1%. The earnings per share also saw a rise, reaching ₹4.87 in Q4FY26 from ₹4.71 in the preceding quarter and ₹4.14 in the same quarter last year, marking a 3.4% QoQ and 17.6% YoY increase.

Operating Metrics

The total expenses for Sai Life Sciences Ltd were recorded at ₹478.72 crores in Q4FY26, up from ₹422.39 crores in Q3FY26, which represents a QoQ increase of 13.3%. Compared to Q4FY25, where expenses were ₹470.31 crores, the YoY growth in expenses is 1.8%. The tax expense in the fourth quarter of FY26 was ₹34.99 crores, a slight increase from ₹33.79 crores in the previous quarter and ₹30.53 crores in the same quarter of the previous year, reflecting a QoQ rise of 3.6% and a YoY increase of 14.6%. These metrics suggest that while the company has managed to increase its income and profitability, it has also experienced a rise in operating expenses during this period.